Pharma Sector Faces Post-Revlimid Challenges and Semaglutide Opportunities

The pharma sector has seen strong growth post-Covid, with top companies growing their revenues and earnings significantly.

However, the sector faces a challenge with the upcoming expiry of the Revlimid patent in 2026, which has been a major revenue source for several companies.

At the same time, there's a new opportunity with Semaglutide, a drug for diabetes and weight loss, which could drive future growth.

The transition from Revlimid to Semaglutide may not be smooth, and companies will need to invest heavily and execute well to maintain their profitability.

Investors should expect some margin compression in 2026 as companies navigate this transition.